Virus News and Research

Latest Virus News and Research

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zila, leader in the prevention and detection of oral diseases, today introduced an angled exam mirror as part of the ViziLite Plus oral lesion identification and marking system. The autoclavable mirror attaches to the top of the ViziLite Plus lightstick retractor, enhancing dental professionals' ability to see oral lesions during a comprehensive oral cancer screening procedure.

28 Jun 2010

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

OraSure Technologies, Inc. announced today that its OraQuick Hepatitis C Rapid Antibody Test has been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States.

28 Jun 2010

FDA approves OraQuick HCV Rapid Antibody Test for HCV

The U.S. Food and Drug Administration today announced approval of the first rapid blood test for antibodies to the hepatitis C virus for individuals 15 years and older.

25 Jun 2010

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

25 Jun 2010

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Scientists have shown that a specific virus can interact with a mutation in the host's genes to trigger disease. The observation may help explain why many people with disease risk genes do not actually develop disease.

25 Jun 2010

Editors of Canadian Medical Association Journal warn polio outbreak in Tajikistan could spread

"A large polio outbreak in Tajikistan - Europe's first in years - has the potential to further spread the dangerous virus to other regions of the world, the [editors of] the Canadian Medical Association Journal [CMAJ] warned Wednesday" in an editorial appearing in the journal, the Canadian Press reports.

25 Jun 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells.

25 Jun 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

AGTC, Icagen complete agreement for purchase and sale of patent rights

AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.

24 Jun 2010

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

The licensing and distribution agreement allows ABL to directly host COMET (COntext-based Modeling for Expeditious Typing) subtyping tool developed at CRP-Santé within the TherapyEdge servers; it will mainly interact with the ViroScore Suite system to characterize HIV-1 virus subtypes.

24 Jun 2010

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the IBC 6th Annual Cell Line Development and Engineering conference held in San Francisco, California from June 21 - 24, 2010.

24 Jun 2010

Telefonica Mexico, Myriad Group nominated for 'Service: Social Use' at 2010 Global Messaging Awards

Telefonica Mexico and Myriad Group AG, in partnership with the Mexican Federal Ministry of Health and researchers at the Harvard School of Public Health, today announced that their combined effort in conducting a H1N1 flu survey via mobile phones was named a finalist for 'Messaging Application or Service: Social Use' at the 2010 Global Messaging Awards.

24 Jun 2010

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

24 Jun 2010

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

Update on Regulus and sanofi-aventis collaboration

Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced today that, as a result of the newly formed alliance Regulus has established with sanofi-aventis, each company will receive a payment of $1.8 million from Regulus. This represents 7.5% of the $25 million upfront payment from sanofi-aventis to Regulus.

23 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Understanding HIV viral protein structure could lead to new molecular medicines: Study

The UK's National Physical Laboratory is involved in a collaborative project that is helping to further the understanding of HIV viral protein structure which could lead to new molecular medicines.

23 Jun 2010

AIDS specialist leaves Calif. practice, citing rising costs

A long-time San Francisco AIDS specialist is closing his clinic and moving to Manhattan because of frustration with the insurance industry and the rising cost of practicing medicine, the San Francisco Chronicle reports. "The bottom line is, you cannot make a living practicing medicine unless you work at least 50 to 60 hours a week," said Dr. Marcus Conant, one of the first AIDS doctors in the area. "I'm not the only doctor who's getting to the point where it's not worth it."

23 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

Virus News and Research

Latest Virus News and Research

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

FDA approves OraQuick HCV Rapid Antibody Test for HCV

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Editors of Canadian Medical Association Journal warn polio outbreak in Tajikistan could spread

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

AGTC, Icagen complete agreement for purchase and sale of patent rights

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Telefonica Mexico, Myriad Group nominated for 'Service: Social Use' at 2010 Global Messaging Awards

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

Update on Regulus and sanofi-aventis collaboration

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Understanding HIV viral protein structure could lead to new molecular medicines: Study

AIDS specialist leaves Calif. practice, citing rising costs

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in